|
1
|
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks.
|
Arch Intern Med
|
2003
|
4.08
|
|
2
|
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.
|
Ann Intern Med
|
2009
|
2.25
|
|
3
|
Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms.
|
Kidney Int
|
2012
|
1.66
|
|
4
|
Prevention of radiocontrast-induced nephropathy.
|
Am J Kidney Dis
|
2004
|
1.56
|
|
5
|
Are 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors renoprotective?
|
J Am Soc Nephrol
|
2005
|
1.04
|
|
6
|
Hypertension and chronic kidney disease progression: why the suboptimal outcomes?
|
Am J Med
|
2012
|
0.83
|
|
7
|
Comparative effects on dynamic renal potassium excretion of ACE inhibition versus angiotensin receptor blockade in hypertensive patients with type II diabetes mellitus.
|
J Clin Pharmacol
|
2002
|
0.80
|
|
8
|
Relationship between erythropoietin administration and alterations of renin-angiotensin-aldosterone.
|
J Renin Angiotensin Aldosterone Syst
|
2006
|
0.78
|
|
9
|
Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.
|
Am J Hypertens
|
2004
|
0.76
|
|
10
|
Aldosterone and large artery vessels.
|
Hypertension
|
2006
|
0.76
|
|
11
|
Hyperkalemia as a constraint to therapy with combination Renin-Angiotensin system blockade: the elephant in the room.
|
J Clin Hypertens (Greenwich)
|
2009
|
0.76
|
|
12
|
Effectiveness of patiromer in the treatment of hyperkalemia in chronic kidney disease patients with hypertension on diuretics.
|
J Hypertens
|
2017
|
0.75
|
|
13
|
OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD.
|
J Hypertens
|
2016
|
0.75
|
|
14
|
Arrhythmias and sudden cardiac death in hemodialysis patients. Temporal profile, electrolyte abnormalities, and potential targeted therapies.
|
Nephrol News Issues
|
2016
|
0.75
|
|
15
|
The use of calcium antagonists in the treatment of hypertensive persons with kidney disease.
|
Curr Hypertens Rep
|
2002
|
0.75
|
|
16
|
Dopamine-1 receptor agonist: renal effects and its potential role in the management of radiocontrast-induced nephropathy.
|
J Clin Pharmacol
|
2004
|
0.75
|
|
17
|
Cyclooxygenase-2 expression and function in renal pathophysiology.
|
J Hypertens Suppl
|
2002
|
0.75
|
|
18
|
Clinical and electrophysiological consequences of hyperkalemia.
|
Nephrol News Issues
|
2016
|
0.75
|
|
19
|
Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
|
Clin J Am Soc Nephrol
|
2006
|
0.75
|
|
20
|
OS 19-04 CHRONIC DIURETIC THERAPY DOES NOT IMPAIR THE EFFECTIVENESS OF PATIROMER IN HYPERKALEMIC PATIENTS WITH CKD.
|
J Hypertens
|
2016
|
0.75
|